Analyse Silo Pharma, Inc. (SILO) — Kairos Score 45/100

À propos de Silo Pharma, Inc.

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Informations clés

🕴️ Activité des initiés (90 jours)

0 transactions — 0 achats et 0 ventes déclarés par les dirigeants de Silo Pharma, Inc..

🏦 Hedge Funds

1 fonds institutionnels déclarent une position sur SILO dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

6 articles récents sur SILO.

• Is Silo Pharma, Inc. (SILO) Stock an AI Opportunity After NVIDIA Partnership Boosts QwikAgents Platform?
• Silo Pharma Shares Slide After Announcing Up to $11.7 Million Private Placement (SILO)

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.